Title 19 Promis 3
3 · ProMIS Neurosciences Inc. · Filed Dec 27, 2023
Insider Transaction Report
Form 3
Title 19 Promis
Other
Holdings
- 1,110,513
Common Shares, no par value
Warrants to Purchase Common Shares, no par value
→ Common Shares (26,597 underlying)Warrants to Purchase Common Shares, no par value
→ Common Shares (797,872 underlying)Warrants to Purchase Common Shares, no par value
→ Common Shares (51,562 underlying)Series 2 Preferred Shares, no par value
→ Common Shares (500,000 underlying)
Footnotes (4)
- [F1]Consists of 51,562 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $0.21 per whole warrant. These warrants are currently exercisable and expire on August 24, 2026.
- [F2]Consists of 26,597 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $7.50 per whole warrant. These warrants are part of Units, each consisting of one Common Share and one-quarter of one warrant to purchase one Common Share. The purchase price for each Unit was $5.40. These warrants are currently exercisable and expire on April 11, 2028, the fifth anniversary of the date the warrants first became exercisable.
- [F3]Consists of 797,872 warrants to purchase Common Shares, each exercisable to purchase one Common Share at an exercise price of $1.75 per whole warrant beginning February 23, 2024. These warrants expire on February 23, 2029, the fifth anniversary of the date the warrants first become exercisable.
- [F4]The Series 2 Preferred Shares are nonvoting and noninterest bearing and are currently convertible at a 1:1 ratio into Common Shares at the option of the holder. The Series 2 Preferred Shares will involuntarily convert into Common Shares upon cumulative qualified equity financing in excess of $14 million.